Literature DB >> 1450662

Sequences within the R region of the long terminal repeat activate basal transcription from the HIV-1 promoter.

K A Boris-Lawrie1, J N Brady, A Kumar.   

Abstract

The importance of the R region in basal human immunodeficiency virus type 1 (HIV-1) transcription was addressed by comparing a panel of HIV-1 R region mutants using in vitro and in vivo assays. Using deletion, base substitution mutants, and compensatory mutants, the precise R region sequences essential for basal HIV-1 promoter activity in vitro were mapped to sequences between +17 to +21. Within this regulatory domain, nucleotides +19 and +21 appear to be critical. The effect of these mutations on steady state RNA levels in transfected cells has been analyzed by S1 nuclease protection assay using uniformly labeled probes. Two main conclusions may be drawn from these studies. First, HIV-1 basal transcription is abundant, with the majority of correctly initiated transcripts truncated between sequences +57 to +70. Second, analysis of the compensatory mutants indicates the secondary structure of the nascent R region RNA is not an obligate requirement for the production of the truncated transcripts. Mutations in R region primary sequence that selectively abolish the production of the truncated transcripts in vivo also exhibit reduced promoter activity in vitro. The appearance of high levels of truncated transcripts raise the interesting possibility that-similar to c-myc, c-myb, and c-fos--basal HIV-1 expression is regulated by transcription elongation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1450662      PMCID: PMC6057376     

Source DB:  PubMed          Journal:  Gene Expr        ISSN: 1052-2166


  73 in total

1.  Characterization of cellular proteins recognizing the HIV enhancer using a microscale DNA-affinity precipitation assay.

Authors:  B R Franza; S F Josephs; M Z Gilman; W Ryan; B Clarkson
Journal:  Nature       Date:  1987 Nov 26-Dec 2       Impact factor: 49.962

2.  Structural requirements for trans activation of human immunodeficiency virus type 1 long terminal repeat-directed gene expression by tat: importance of base pairing, loop sequence, and bulges in the tat-responsive sequence.

Authors:  S Roy; N T Parkin; C Rosen; J Itovitch; N Sonenberg
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

Review 3.  Regulatory pathways governing HIV-1 replication.

Authors:  B R Cullen; W C Greene
Journal:  Cell       Date:  1989-08-11       Impact factor: 41.582

4.  Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.

Authors:  T Folks; J Kelly; S Benn; A Kinter; J Justement; J Gold; R Redfield; K W Sell; A S Fauci
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

5.  A transcriptional arrest mechanism involved in controlling constitutive levels of mouse c-myb mRNA.

Authors:  R J Watson
Journal:  Oncogene       Date:  1988-03       Impact factor: 9.867

6.  Interaction of enhancer-binding protein EBP1 (NF-kappa B) with the human immunodeficiency virus type 1 enhancer.

Authors:  L Clark; J R Matthews; R T Hay
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

7.  Genetic and physical analysis of the chicken tk gene.

Authors:  G F Merrill; R M Harland; M Groudine; S L McKnight
Journal:  Mol Cell Biol       Date:  1984-09       Impact factor: 4.272

8.  A cis downstream element participates in regulation of in vitro transcription initiation from the P38 promoter of minute virus of mice.

Authors:  A Krauskopf; O Resnekov; Y Aloni
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

9.  Multiple transcriptional regulatory domains in the human immunodeficiency virus type 1 long terminal repeat are involved in basal and E1A/E1B-induced promoter activity.

Authors:  S Kliewer; J Garcia; L Pearson; E Soultanakis; A Dasgupta; R Gaynor
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

View more
  7 in total

1.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

2.  A human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activity.

Authors:  S Nekhai; R R Shukla; A Kumar
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Coordination of transcription factor phosphorylation and histone methylation by the P-TEFb kinase during human immunodeficiency virus type 1 transcription.

Authors:  Meisheng Zhou; Longwen Deng; Vincent Lacoste; Hyeon Ung Park; Anne Pumfery; Fatah Kashanchi; John N Brady; Ajit Kumar
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription.

Authors:  Sergei Nekhai; Meisheng Zhou; Anne Fernandez; William S Lane; Ned J C Lamb; John Brady; Ajit Kumar
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

5.  Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription.

Authors:  M Zhou; M A Halanski; M F Radonovich; F Kashanchi; J Peng; D H Price; J N Brady
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

6.  Identification of c-fos-responsive elements downstream of TAR in the long terminal repeat of human immunodeficiency virus type-1.

Authors:  K A Roebuck; D A Brenner; M F Kagnoff
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

7.  Human transcription factor YY1 could upregulate the HIV-1 gene expression.

Authors:  Kyung Lee Yu; Yu Mi Jung; Seong Hyun Park; Seong Deok Lee; Ji Chang You
Journal:  BMB Rep       Date:  2020-05       Impact factor: 4.778

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.